CA-125 and Ovarian Cancer
CA-125 is most strongly associated with epithelial ovarian cancer (EOC), particularly high-grade serous carcinoma, where it is elevated in approximately 85% of patients with advanced disease. 1
Primary Cancer Association
Epithelial ovarian cancer represents the definitive malignancy for CA-125 elevation. According to the 2023 ESMO Clinical Practice Guidelines, serum CA-125 measurement is the standard diagnostic aid for suspected EOC and forms part of the core diagnostic work-up 1. The marker demonstrates:
- 85% sensitivity in advanced-stage disease (FIGO stages III-IV)
- 50% sensitivity in early-stage disease (FIGO stage I)
- Highest elevation in high-grade serous carcinoma (70% of EOC cases)
Important Clinical Caveats
Specificity Limitations
CA-125 elevation is NOT specific to ovarian cancer and can be elevated in multiple conditions 1:
Benign gynecologic conditions:
- Endometriosis
- Ovarian cysts
- Menstruation
- Pregnancy
Other malignancies:
- Endometrial cancer
- Fallopian tube cancer
- Pancreatic cancer
- Breast cancer
- Colon cancer
- Lung cancer
Histologic Subtype Variations
The utility of CA-125 varies substantially by EOC histologic subtype 2:
- High-grade serous carcinoma: Highest sensitivity (81.8%)
- Clear cell and mucinous carcinomas: Markedly lower sensitivity (28.6%)
This histologic variation is clinically critical—relying solely on CA-125 for surveillance in clear cell or mucinous subtypes will miss approximately 70% of recurrences 2.
Racial and Ethnic Disparities
Recent evidence demonstrates that American Indian and Black patients are 23% less likely to have elevated CA-125 at ovarian cancer diagnosis compared to White patients (AOR 0.77) 3. Current CA-125 thresholds were developed from predominantly White populations, potentially contributing to delayed diagnoses in racially diverse patients.
Clinical Applications
Diagnostic work-up: When CA-125 is elevated in the setting of a pelvic mass, additional markers should be obtained 1:
- CEA and CA 19-9 if mucinous carcinoma suspected
- If CA-125/CEA ratio <25:1, consider gastrointestinal primary with endoscopy
Monitoring during treatment: CA-125 demonstrates 89-92% concordance with clinical disease status during chemotherapy 4, 5, though concordance drops significantly during PARP inhibitor maintenance therapy where 56% of RECIST progressions occur without CA-125 elevation 6.
Surveillance limitations: For patients on maintenance PARP inhibitors with platinum-sensitive relapsed disease, periodic CT imaging is essential as CA-125 has only 44% negative predictive value—meaning a normal CA-125 does NOT exclude progression 6.